Rapport Therapeutics
RAPP
161 hedge funds and large institutions have $2.13B invested in Rapport Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 57 increasing their positions, 46 reducing their positions, and 12 closing their positions.
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
30% more capital invested
Capital invested by funds: $1.64B → $2.13B (+$488M)
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
10% more funds holding
Funds holding: 147 → 161 (+14)
2.59% less ownership
Funds ownership: 109.8% → 107.21% (-2.6%)
19% less call options, than puts
Call options by funds: $363K | Put options by funds: $450K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Algert Global
San Francisco,
California
|
+$8.23M |
| 2 |
BlackRock
New York
|
+$7.12M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.94M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.06M |
| 5 |
Morgan Stanley
New York
|
+$4.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGV
TRV GP V
Boston,
Massachusetts
|
-$31.4M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$26M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$10.1M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$8.36M |
RAPP Hedge Fund Activity: Q2 2026 in Review
161 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q2 2026, worth a combined $2.13B — up 30% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RAPP positions and 12 closed out — a net gain of 17 holders — while 57 added to existing stakes and 46 trimmed.
The largest buyer was Algert Global, opening a new position worth an estimated $8.23M. The largest seller was TRV GP V, cutting an estimated $31.4M.
- 161 institutional investors held Rapport Therapeutics (RAPP) as of Q2 2026, up from 147 in Q1 2026.
- Funds reported $2.13B of Rapport Therapeutics stock for Q2 2026, up 30% quarter-over-quarter.
- 29 funds opened new Rapport Therapeutics positions in Q2 2026 and 12 closed out, a net change of +17 holders.
- The largest Rapport Therapeutics buyer in Q2 2026 was Algert Global, an estimated $8.23M added.
- The largest Rapport Therapeutics seller in Q2 2026 was TRV GP V, an estimated $31.4M sold.
Based on aggregated 13F filings for Q2 2026.